Rhinitis, Allergic Clinical Trial
Official title:
A Randomized, Double-blind, Placebo Controlled Study to Assess the Safety and Tolerability of HAL-MRE1 Subcutaneous Immunotherapy in Adult Subjects With Ragweed Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma
Verified date | August 2019 |
Source | HAL Allergy |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of this first-in-human phase I study is to assess the safety and tolerability of
HAL-MRE1 subcutaneous immunotherapy in subjects suffering from ragweed pollen-induced
allergic rhinitis/rhinoconjunctivitis with or without asthma.
The study has 4 treatment groups: 1 placebo group and 3 groups treated with different doses
of HAL-MRE1.
Status | Completed |
Enrollment | 45 |
Est. completion date | May 17, 2019 |
Est. primary completion date | May 17, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: 1. Signed informed consent. 2. Male or female subjects aged =18 and =65 years. 3. Documented diagnosis of allergic rhinitis/rhinoconjunctivitis (ARC) to ragweed pollen. A documented diagnosis is a documented medical history of ARC symptoms that required treatment after ragweed pollen exposure. Subjects experienced allergy symptoms that required treatment during the previous 2 ragweed seasons, with or without concomitant asthma (asthma must be controlled). 4. Positive nasal provocation test for ragweed pollen at screening or within the last 6 months. 5. Positive skin prick test to ragweed allergen at screening or within the last 6 months. 6. Positive serum specific IgE test for ragweed allergen (IgE level =0.7 U/mL). 7. Forced expiratory volume >70 % or peak expiratory flow >80 % of predicted value. 8. For asthmatic subjects: asthma control test (ACT) score =20. 9. Subjects are capable and willing to maintain a log of adverse events and concomitant medication throughout the study, as well as to complete a diary 24 hours post investigational medical product injection. 10. Negative pregnancy test at screening for females of childbearing potential. 11. Females of childbearing age must be using an effective method of contraception to prevent pregnancy and agree to continue to practice an acceptable method of contraception for the duration of participation in the study. Contraceptive measures considered adequate are: 1. hormonal contraceptives such as contraceptive pills, transdermal patches, intrauterine devices, intrauterine system implants, or vaginal rings (started at least 4 weeks prior to investigational medical product administration). 2. double barrier methods e.g. condom or occlusive cap (diaphragm or cervical/vault caps) plus spermicidal agent. 3. sterilization (male or female). 4. participants who are postmenopausal (12 consecutive months without a period) for at least 2 years. 5. sexual abstinence or having no sexual relationship with a man. Exclusion Criteria: 1. History of anaphylaxis with cardio respiratory symptoms (food allergy, venom allergy, drugs or/and idiopathic reaction). 2. Alcohol, drug or medication abuse in the past. 3. Any clinically significant abnormal laboratory parameter at screening as per investigator's discretion. 4. Clinically relevant sensitization to other allergens if clinical symptoms are expected during the study. 5. Uncontrolled asthma. 6. Participation in a clinical interventional study within the last 3 months (e.g. new investigational drug or biological), or plans to participate in another clinical trial during this study, or participation in an observational study (e.g. post marketing study) within the last 30 days unless the observational study aimed to investigate the intradermal test. 7. Subjects who received immunotherapy for any specific allergen 3 years prior to screening or during the study period. 8. Subjects who were ever treated with any ragweed allergen specific immunotherapy. 9. Severe immune disorders (including auto-immune diseases) and/or diseases requiring immunosuppressive drugs. 10. Subjects undergoing any immunosuppressive treatment (including anti-IgE therapy) within the last 6 months prior to inclusion in the study as well as during the study. 11. Active malignancies or any malignant disease during the 5 years prior to screening. 12. Severe uncontrolled diseases that, in the opinion of the investigator, could increase the risk for subjects participating in the study, including but not limited to: any severe or unstable lung diseases; endocrine diseases; clinically significant renal or hepatic diseases, or hematological disorders; or severe ongoing symptomatic allergic diseases. 13. Active or acute inflammation or infection of the target organs (nose, eyes) at screening. 14. Diseases with a contra-indication for the use of adrenaline (e.g. hyperthyroidism, glaucoma). 15. Lactation. 16. Severe psychiatric, psychological, or neurological disorders. 17. Subjects who have any direct working relationship with the (sub-) investigator or study site personnel or are first degree relatives or partners of the investigator or study site personnel or are employees of the sponsor. 18. Known allergy or hypersensitivity to an excipient in the study drug or placebo. 19. Subjects receiving the prohibited previous and concomitant medication. |
Country | Name | City | State |
---|---|---|---|
Canada | Inflamax Research Inc. | Mississauga |
Lead Sponsor | Collaborator |
---|---|
HAL Allergy |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Occurence of local and systemic reactions | Number, intensity and seriousness of early (within 30 mins from injection), delayed (within 30mins and 3 hours from injection) and late (from 3 hours to 24 hours after injection) local reactions (>8 cm wheal size swelling at injection site) as well as early, delayed and late systemic reactions. | Through study completion, approximately 10 weeks | |
Secondary | Occurence of other local reactions | Number, intensity and seriousness of other local reactions like itching, pain and redness at injection site. | Through study completion, approximately 10 weeks | |
Secondary | Occurrence of treatment emergent adverse events | Treatment emergent adverse events will be collected by reporting of adverse events and by clinical relevant changes in e.g. laboratory values, vital signs, physical exam, and lung function in plasma and urine | Through study completion, approximately of 10 weeks | |
Secondary | Number of subjects that reach maximum dose | The number of subjects in each cohort who reach the maximum dose is indicative of HAL-MRE1 tolerability. | Through study completion, approximately of 10 weeks | |
Secondary | Number of injections to reach maintenance dose | The number of injections that subjects in each cohort need to reach the maximum dose will provide an indication of HAL-MRE1 tolerability. | Through study completion, approximately of 10 weeks | |
Secondary | Immunoglobulin Levels | Short term pharmacodynamic effects of HAL-MRE1 will be measured by determining the change in serum levels of allergen specific immunoglobulins (IgE, IgG and IgG4) pre- and post-study treatment in the HAL-MRE versus placebo treated groups. | Pre-treatment and after the repeated maintenance dose visit (after 8 to 10 weeks) | |
Secondary | Change in wheal size after skin prick test | Exploratory efficacy data will be obtained by measuring the change in wheal size following skin prick test with ragweed extract pre- and post-treatment in the HAL-MRE1 versus placebo treated groups. | Pre-treatment and after the repeated maintenance dose visit (after 8 to 10 weeks) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02424539 -
A Study to Compare the Efficacy and Safety of Fluticasone Furoate Nasal Sprays (FFNS) 55 Microgram (mcg) and 110 mcg in Chinese Pediatric Subjects With Allergic Rhinitis (AR)
|
Phase 4 | |
Completed |
NCT02486159 -
The Oligonucleotide Chip Analysis for Allergic Rhinitis Treatment in Herbal Plaster and Acupuncture
|
N/A | |
Completed |
NCT00770315 -
Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234)
|
Phase 3 | |
Completed |
NCT00771160 -
MK0476 Study in Adult Patients With Perennial Allergic Rhinitis (0476-397)(COMPLETED)
|
Phase 3 | |
Completed |
NCT00834119 -
Assessment of Intranasal Steroids in Allergic Rhinitis When Used Alone or in Combination With an Oral Antihistamine (Study P03270)
|
Phase 4 | |
Recruiting |
NCT04435990 -
Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites
|
Phase 3 | |
Recruiting |
NCT05177744 -
Toxicity of Micro and Nano Plastics Combined With Environmental Contaminants on the Risk of Allergic Disease
|
||
Recruiting |
NCT05621356 -
Monitoring Allergen Immunotherapy in Allergic Rhinitis
|
||
Not yet recruiting |
NCT06330974 -
Allergy, Asthma, and Atopic Eczema in Finland
|
||
Completed |
NCT04645979 -
A Study to Learn What Participants Think of Treatment With Betamethasone Plus Loratadine to Treat Their Acute Allergic Rhinitis, Also Known as Hay Fever in Mexico
|
||
Completed |
NCT05122143 -
Efficacy and Safety of AM-301 on Allergic Symptoms of Perennial Allergic Rhinitis Sufferers
|
N/A | |
Completed |
NCT05901532 -
Nasal Irrigation With Chinese Herbal Medicine as an Adjunctive Treatment in Allergic Rhinitis
|
Phase 2 | |
Terminated |
NCT02722083 -
Exploratory Study for Allergy Relief Onset
|
Phase 2 | |
Recruiting |
NCT05656482 -
Ability of a Cat Food to Reduce Respiratory Symptoms in Cat Allergic Patients
|
||
Recruiting |
NCT04898283 -
Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.
|
Phase 3 | |
Recruiting |
NCT06436534 -
Efficacy and Safety of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic Rhinitis
|
N/A | |
Recruiting |
NCT05922176 -
Biomarker Screening for Immunotherapy Response Evaluation Using Microneedle Patch in Patients With Allergic Rhinitis
|
||
Completed |
NCT02679105 -
Intralymphatic Immunotherapy in Increasing Doses, After Subcutaneous Immunotherapy
|
Phase 2/Phase 3 | |
Completed |
NCT01104012 -
Validation of Proteomic Analyses for Allergic Asthma and Rhinitis
|
N/A | |
Completed |
NCT03375775 -
Evaluation of Subcutaneous Immunotherapy Towards Pollen in Children
|
N/A |